Since CD4+ anti-JCV responses in MS patients have been shown to depend primarily on Th1 cells, the reliance of this population on VLA-4/VCAM-1 contributes to the inability of natalizumab-treated patients to effectively clear JCV from the CNS (62). Here, CD4 is linked to myeloid sarcoma.